Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma

Published:2022-05-26 Issue:6 Volume:36 Page:
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:The FASEB Journal

Author:

Guo Yinglin¹^ORCID,Peng Qing¹,Hao Liyuan¹,Ji Jingmin¹,Zhang Zhiqin¹,Xue Yu¹,Liu Yiwei¹,Gao Yuting¹,Li Caige¹,Shi Xinli¹^ORCID

Affiliation:

1. Department of Pathobiology and Immunology Hebei University of Chinese Medicine Shijiazhuang China

Funder

National Natural Science Foundation of China-Yunnan Joint Fund

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.202200171R

Reference67 articles.

1. Hepatocellular carcinoma

2. Erratum: Global cancer statistics: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;CA Cancer J Clin,2018

3. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

4. Targeting T Cell Co-receptors for Cancer Therapy

5. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bile Acids and Liver Cancer: Molecular Mechanism and Therapeutic Prospects;Pharmaceuticals;2024-08-30

2. Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review);International Journal of Oncology;2024-07-31

3. Dihydroartemisinin modulated arachidonic acid metabolism and mitigated liver inflammation by inhibiting the activation of 5-LOX and COX-2;Heliyon;2024-07

4. Bile acids and coronavirus disease 2019;Acta Pharmaceutica Sinica B;2024-05

5. Targeting YAP1 to improve the efficacy of immune checkpoint inhibitors in liver cancer: mechanism and strategy;Frontiers in Immunology;2024-03-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3